Melphalan Market by Dosage (Product (Kit, Tablet, Film Coated and Injection Powder, lyophilized for Solution) Route (Oral (2 mg/1, 2MG, 5MG) and Intra-arterial, Intravenous 50 mg/10 ml), by Indication (Multiple Myeloma, Ovarian Cancer, Neuroblastoma, Rhabdomyosarcoma, Breast Cancer, Used in some Conditioning Regimens Prior to Bone Marrow Transplant, Non-resectable Epithelial Carcinoma of the Ovary, Recurrent or Unresectable in-transit Metastatic Melanoma, Treatment of Amyloidosis with Prednisone, Adjunct to Surgery in the Treatment of Breast Cancer and Others (Severe Hodgkin Lymphoma, etc.)) By Region (Northeast, Midwest, Wets and South) – United States Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2020 - 2028
Industry Trends
United States Melphalan market was valued at US$ 137.85 million in 2019 and is expected to reach US$ 203.73 million by 2028, growing at a CAGR of 4.4% over the forecast period. Melphalan is a chemotherapy medication and is often referred to as Alkeran. The drug is used for treatment of various type of cancers like multiple myeloma, breast cancer, and ovarian cancer amongst others. Melphalan is one of a group of medicines called alkylating agents; it binds to one of the DNA strands of a cancer cell. The genetic code that is in the nucleus of all cells in animals and plants is DNA. The drug controls everything the cell does and helps in eliminating the cell growth and the then it is then unlikely for the cell to expand and break into 2 new cells.
Melphalan is a medication which can be given as an injection through a vein and is also available in tablet form. The drug comes as a white tablet which is taken while the stomach is empty and the tablets needs to be stored in a cool place. The duration of therapy depends on the types of medications patients take, how well the body reacts to them, and the type of cancer the patient is having. The drug is majorly used for cancer treatment but the physicians also prescribe the drug for treatment of other diseases. The amount of drug to be prescribed depends on various factors such as height and weight of the patient and also considers general health problems of the patient. Presently Melphalan is available in the United States market in the form of capsules as well as injection. There are many suppliers as well as distributors currently active in the market. The Melphalan drug manufacturing companies are striving to maintain a steady supply of the drug in the market. As it is on the list of essential drugs a steady flow of the drug is being maintained in the market for the patients suffering from cancer.
Another factor which will boost the growth of Melphalan market is the increasing number of cancer patients in United States. Cancer has a very serious impact in the United States, more than 1.8 million new cases are being registered in the country and the number is increasing at a very high rate. Most common cancers in United States are prostate cancer, lung cancer, breast cancer and pancreatic cancer amongst others. In order to reduce the mortality rate amongst cancer patients the government is undertaking many initiatives and is investing more on the R&D projects associated with finding cure to cancer. Government spending on cancer treatment and supplying of advanced medication has increased over the years. 1 out of 6 deaths in United States is due to cancer this will boost the demand for Melphalan drugs in the market. In order to reduce the death rate of patients diagnosed with cancer the services are getting people centred and the demand for effective medication to treat cancer is increasing. Melphalan manufacturers and suppliers are keeping constant supply of the drug in the market. As the drug is used to treat several types of cancer like ovarian cancer, multiple myeloma and breast cancer will fuel the demand for the Melphalan drug over the forecast period.
Melphalan is used in various preparations and is promoted in numerous brand names. The number of patients diagnosed with multiple myeloma is rising day by day. The number of patients with multiple myeloma has increased rapidly in United States over the years. Considering the year 2020 there are more than 32000 cases recorded for multiple myeloma in United States and it is expected that more than 12000 deaths will occur due to this. Multiple myeloma is the most common blood cancer in United States and the overall death rate due to multiple myeloma has risen over the years. Melphalan is used majorly for the treatment of multiple myeloma aiding in increasing the life expectancy of the patients this factor will boost the adoption of Melphalan for the treatment of multiple myeloma over the forecast period. Melphalan is an alkylating agent which attaches the chemical molecules to DNA, Melphalan reduces the rapidly dividing myeloma cells from replicating and helps in controlling cell duplication. For myeloma high doses of Melphalan are administered and this high dosage is more effective in reducing the myeloma cells. Melphalan along with Autologous stem-cell transplantation (ASCT) has yielded better outcomes than the traditional chemotherapy medication. 65 years old or younger patients have shown promising results for the treatment thus boosting the adoption of the drug in the years to come. The overall rate of survival for patients with multiple myeloma is 74% and if the cancer is spread to other parts then the survival rate gets decreased to 51%. Due to advancement in chemotherapy medication the overall survival rate has increased in the United States over the years. Government initiative towards reducing the number of deaths in cancer patients and advanced medication for treatment of cancer is propelling the growth of Melphalan market over the forecast period.
However the drug has many side effects like allergic reaction, mouth sores, diarrhea, and hair loss amongst others. Also using Melphalan the patient can develop infection more easily and that infection can be serious leading to death. This could hamper the growth of Melphalan market over the forecast period. By taking this drug there is a slight chance of developing blood cancer such as leukemia also the major side effect that occurs is low blood count among patients, these factors could refrain the growth of the market over the forecast period. However the effects of the drug are reversible and are likely to go away when the medication is complete, the healthcare professionals constantly monitor the patients administered with Melphalan. In order to prevent side effects in patients the professionals continuously check the response of patients to the therapy. The drug is being used in many experiments related to cancer and is showing promising results. Melphalan can be used as an anti-cancer drug by giving high dosage to the patients for treatment of solid tumor malignancies. Due to efficient results of the drug for treatment of various cancer and efficient outcomes are increasing the demand for Melphalan over the forecast period.
Dosage Insights
In the dosage segment, injection powder, lyophilized, for solution has the highest penetration in 2019 and is expected to continue the same trend over the forecast period. Melphalan has highest usage as an injection through vein and high doses of Melphalan are administered through vein as high doses show promising results. As intravenous use is the highest the use of injection powder increases also 50 mg per vial lyophilized powder is used is a single dose vial. Thus, injection powder, lyophilized, for solution will lead the market over the next eight years.
Route Insights
Based on route Intra-arterial, Intravenous 50 mg/10 ml captured the highest share in 2019. Patients suffering from multiple myeloma are given the dose through an IV. The intravenous injection has shown promising results in the treatment of multiple myeloma thus increasing the demand for the dosage through intravenous route over the forecast period.
Indication Insights
Based on Indication the multiple myeloma segments will lead the market over the forecast period. Melphalan is used for treatment of various type of cancer and this chemotherapy medication is highly prescribed for patients suffering from multiple myeloma and there is a rise in use of Melphalan for patients suffering with multiple myeloma. The number of patients diagnosed with multiple myeloma is increasing at a rapid rate in United States thus increasing the need for Melphalan drug over the forecast period.
Region Insights
In United States, the number of people diagnosed with cancer is rising at a rapid rate. The number of deaths relate to cancer are rising in United States. As a result, an increasing need for advanced chemotherapy medication for patients suffering from cancer is needed at an urgent basis. There are increasing government initiatives towards reducing the death rate in cancer patients by providing state of the art medication. These factors are fuelling the demand for melphalan in the United States currently and are expected to aid the market over the forecast period.
Melphalan Market Revenue & Forecast, (US$ Million), 2020 – 2028
Competitive Landscape
The report provides both, qualitative and quantitative research Melphalan market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contacts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their regional presence, competitors, service offerings and specification amongst others.
Some of the players operating in the United States melphalan market are Acrotech Biopharma, LLC., ApoPharma Inc., CELGENE CORPORATION, Fresenius Kabi USA, LLC, Ingenus Pharmaceuticals, LLC, and Mylan Inc. amongst others.
Melphalan Market:
- By Dosage
- Kit
- Tablet, Film Coated
- Injection Powder, lyophilized, for Solution
- By Route
- Oral (2 mg/1, 2MG, 5MG)
- Intra-arterial, Intravenous 50 mg/10 ml
- By Indication
- Multiple Myeloma
- Ovarian Cancer
- Neuroblastoma
- Rhabdomyosarcoma
- Breast Cancer
- Used in some Conditioning Regimens Prior to Bone Marrow Transplant
- Non-resectable Epithelial Carcinoma of the Ovary
- Recurrent or Unresectable in-transit Metastatic Melanoma
- Treatment of Amyloidosis with Prednisone
- Adjunct to Surgery in the Treatment of Breast Cancer
- Others (Severe Hodgkin Lymphoma, etc.)
- By Region
- Northeast
- Midwest
- West
- South
Table of Contents
1. Market
Scope
1.1. Market
Segmentation
1.2. Years
Considered
1.2.1. Historic
Years: 2015 - 2018
1.2.2. Base
Year: 2019
1.2.3. Forecast
Years: 2020 – 2028
2. Key Target
Audiences
3. Research
Methodology
3.1. Primary
Research
3.1.1. Research
Questionnaire
3.1.2. United
States Percentage Breakdown
3.1.3. Primary
Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary
Research
3.2.1. Paid
Databases
3.2.2. Secondary
Sources
3.3. Market
Size Estimates
3.3.1. Top-Down
Approach
3.3.2. Bottom-Up
Approach
3.4. Data
Triangulation Methodology
3.5. Research
Assumptions
4. Recommendations
and Insights from AMI’s Perspective**
5. Holistic
Overview of Melphalan Market
6. Market
Synopsis: Melphalan Market
7. Melphalan
Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product
Definition
7.1.2. Industry
Development
7.2. Market
Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.3. Trends in
Melphalan Market
7.4. Market
Determinants Radar Chart
7.5. Macro-Economic
and Micro-Economic Indicators: Melphalan Market
7.6. Porter’s
Five Force Analysis
7.7. Impact of
Covid-19 on Melphalan Market
8. United
States Melphalan Market Analysis and Forecasts, 2020 – 2028
8.1. Overview
8.1.1. United
States Melphalan Market Revenue (US$ Mn)
8.2. United
States Melphalan Market Revenue (US$ Mn) and
Forecasts, By Dosage
8.2.1. Kit
8.2.1.1. Definition
8.2.1.2. Market
Penetration, 2018
8.2.1.3. Market
Estimation, 2015 – 2019
8.2.1.4. Market
Forecast, 2020 – 2028
8.2.1.5. Compound
Annual Growth Rate (CAGR)
8.2.1.6. Regional
Bifurcation
8.2.1.6.1. Northeast
8.2.1.6.1.1. Market
Estimation, 2015 – 2019
8.2.1.6.1.2. Market
Forecast, 2020 – 2028
8.2.1.6.2. Midwest
8.2.1.6.2.1. Market
Estimation, 2015 – 2019
8.2.1.6.2.2. Market
Forecast, 2020 – 2028
8.2.1.6.3. West
8.2.1.6.3.1. Market
Estimation, 2015 – 2019
8.2.1.6.3.2. Market
Forecast, 2020 – 2028
8.2.1.6.4. South
8.2.1.6.4.1. Market
Estimation, 2015 – 2019
8.2.1.6.4.2. Market
Forecast, 2020 – 2028
8.2.2. Tablet,
Film Coated
8.2.2.1. Definition
8.2.2.2. Market
Penetration, 2018
8.2.2.3. Market
Estimation, 2015 – 2019
8.2.2.4. Market
Forecast, 2020 – 2028
8.2.2.5. Compound
Annual Growth Rate (CAGR)
8.2.2.6. Regional
Bifurcation
8.2.2.6.1. Northeast
8.2.2.6.1.1. Market
Estimation, 2015 – 2019
8.2.2.6.1.2. Market
Forecast, 2020 – 2028
8.2.2.6.2. Midwest
8.2.2.6.2.1. Market
Estimation, 2015 – 2019
8.2.2.6.2.2. Market
Forecast, 2020 – 2028
8.2.2.6.3. West
8.2.2.6.3.1. Market
Estimation, 2015 – 2019
8.2.2.6.3.2. Market
Forecast, 2020 – 2028
8.2.2.6.4. South
8.2.2.6.4.1. Market
Estimation, 2015 – 2019
8.2.2.6.4.2. Market
Forecast, 2020 – 2028
8.2.3. Injection
Powder, lyophilized, for Solution
8.2.3.1. Definition
8.2.3.2. Market
Penetration, 2018
8.2.3.3. Market
Estimation, 2015 – 2019
8.2.3.4. Market
Forecast, 2020 – 2028
8.2.3.5. Compound
Annual Growth Rate (CAGR)
8.2.3.6. Regional
Bifurcation
8.2.3.6.1. Northeast
8.2.3.6.1.1. Market
Estimation, 2015 – 2019
8.2.3.6.1.2. Market
Forecast, 2020 – 2028
8.2.3.6.2. Midwest
8.2.3.6.2.1. Market
Estimation, 2015 – 2019
8.2.3.6.2.2. Market
Forecast, 2020 – 2028
8.2.3.6.3. West
8.2.3.6.3.1. Market
Estimation, 2015 – 2019
8.2.3.6.3.2. Market
Forecast, 2020 – 2028
8.2.3.6.4. South
8.2.3.6.4.1. Market
Estimation, 2015 – 2019
8.2.3.6.4.2. Market
Forecast, 2020 – 2028
8.3. Key
Segment for Channeling Investments
8.3.1. By
Dosage
9. United
States Melphalan Market Analysis and Forecasts, 2020 – 2028
9.1. Overview
9.2. United
States Melphalan Market Revenue (US$ Mn) and
Forecasts, By Route
9.2.1. Oral (2
mg/1, 2MG, 5MG)
9.2.1.1. Definition
9.2.1.2. Market
Penetration, 2018
9.2.1.3. Market
Estimation, 2015 – 2019
9.2.1.4. Market
Forecast, 2020 – 2028
9.2.1.5. Compound
Annual Growth Rate (CAGR)
9.2.1.6. Regional
Bifurcation
9.2.1.6.1. Northeast
9.2.1.6.1.1. Market
Estimation, 2015 – 2019
9.2.1.6.1.2. Market
Forecast, 2020 – 2028
9.2.1.6.2. Midwest
9.2.1.6.2.1. Market
Estimation, 2015 – 2019
9.2.1.6.2.2. Market
Forecast, 2020 – 2028
9.2.1.6.3. West
9.2.1.6.3.1. Market
Estimation, 2015 – 2019
9.2.1.6.3.2. Market
Forecast, 2020 – 2028
9.2.1.6.4. South
9.2.1.6.4.1. Market
Estimation, 2015 – 2019
9.2.1.6.4.2. Market
Forecast, 2020 – 2028
9.2.2. Intra-arterial,
Intravenous 50 mg/10 ml
9.2.2.1. Definition
9.2.2.2. Market
Penetration, 2018
9.2.2.3. Market
Estimation, 2015 – 2019
9.2.2.4. Market
Forecast, 2020 – 2028
9.2.2.5. Compound
Annual Growth Rate (CAGR)
9.2.2.6. Regional
Bifurcation
9.2.2.6.1. Northeast
9.2.2.6.1.1. Market
Estimation, 2015 – 2019
9.2.2.6.1.2. Market
Forecast, 2020 – 2028
9.2.2.6.2. Midwest
9.2.2.6.2.1. Market
Estimation, 2015 – 2019
9.2.2.6.2.2. Market
Forecast, 2020 – 2028
9.2.2.6.3. West
9.2.2.6.3.1. Market
Estimation, 2015 – 2019
9.2.2.6.3.2. Market
Forecast, 2020 – 2028
9.2.2.6.4. South
9.2.2.6.4.1. Market
Estimation, 2015 – 2019
9.2.2.6.4.2. Market
Forecast, 2020 – 2028
9.3. Key
Segment for Channeling Investments
9.3.1. By Route
10. United
States Melphalan Market Analysis and Forecasts, 2020 – 2028
10.1. Overview
10.2. United
States Melphalan Market Revenue (US$ Mn) and
Forecasts, By Indication
10.2.1. Multiple
Myeloma
10.2.1.1. Definition
10.2.1.2. Market
Penetration, 2018
10.2.1.3. Market
Estimation, 2015 – 2019
10.2.1.4. Market
Forecast, 2020 – 2028
10.2.1.5. Compound
Annual Growth Rate (CAGR)
10.2.1.6. Regional
Bifurcation
10.2.1.6.1. Northeast
10.2.1.6.1.1. Market
Estimation, 2015 – 2019
10.2.1.6.1.2. Market
Forecast, 2020 – 2028
10.2.1.6.2. Midwest
10.2.1.6.2.1. Market
Estimation, 2015 – 2019
10.2.1.6.2.2. Market
Forecast, 2020 – 2028
10.2.1.6.3. West
10.2.1.6.3.1. Market
Estimation, 2015 – 2019
10.2.1.6.3.2. Market
Forecast, 2020 – 2028
10.2.1.6.4. South
10.2.1.6.4.1. Market
Estimation, 2015 – 2019
10.2.1.6.4.2. Market
Forecast, 2020 – 2028
10.2.2. Ovarian
Cancer
10.2.2.1. Definition
10.2.2.2. Market
Penetration, 2018
10.2.2.3. Market
Estimation, 2015 – 2019
10.2.2.4. Market
Forecast, 2020 – 2028
10.2.2.5. Compound
Annual Growth Rate (CAGR)
10.2.2.6. Regional
Bifurcation
10.2.2.6.1. Northeast
10.2.2.6.1.1. Market
Estimation, 2015 – 2019
10.2.2.6.1.2. Market
Forecast, 2020 – 2028
10.2.2.6.2. Midwest
10.2.2.6.2.1. Market
Estimation, 2015 – 2019
10.2.2.6.2.2. Market
Forecast, 2020 – 2028
10.2.2.6.3. West
10.2.2.6.3.1. Market
Estimation, 2015 – 2019
10.2.2.6.3.2. Market
Forecast, 2020 – 2028
10.2.2.6.4. South
10.2.2.6.4.1. Market
Estimation, 2015 – 2019
10.2.2.6.4.2. Market
Forecast, 2020 – 2028
10.2.3. Neuroblastoma
10.2.3.1. Definition
10.2.3.2. Market
Penetration, 2018
10.2.3.3. Market
Estimation, 2015 – 2019
10.2.3.4. Market
Forecast, 2020 – 2028
10.2.3.5. Compound
Annual Growth Rate (CAGR)
10.2.3.6. Regional
Bifurcation
10.2.3.6.1. Northeast
10.2.3.6.1.1. Market
Estimation, 2015 – 2019
10.2.3.6.1.2. Market
Forecast, 2020 – 2028
10.2.3.6.2. Midwest
10.2.3.6.2.1. Market
Estimation, 2015 – 2019
10.2.3.6.2.2. Market
Forecast, 2020 – 2028
10.2.3.6.3. West
10.2.3.6.3.1. Market
Estimation, 2015 – 2019
10.2.3.6.3.2. Market
Forecast, 2020 – 2028
10.2.3.6.4. South
10.2.3.6.4.1. Market
Estimation, 2015 – 2019
10.2.3.6.4.2. Market
Forecast, 2020 – 2028
10.2.4. Rhabdomyosarcoma
10.2.4.1. Definition
10.2.4.2. Market
Penetration, 2018
10.2.4.3. Market
Estimation, 2015 – 2019
10.2.4.4. Market
Forecast, 2020 – 2028
10.2.4.5. Compound
Annual Growth Rate (CAGR)
10.2.4.6. Regional
Bifurcation
10.2.4.6.1. Northeast
10.2.4.6.1.1. Market
Estimation, 2015 – 2019
10.2.4.6.1.2. Market
Forecast, 2020 – 2028
10.2.4.6.2. Midwest
10.2.4.6.2.1. Market
Estimation, 2015 – 2019
10.2.4.6.2.2. Market
Forecast, 2020 – 2028
10.2.4.6.3. West
10.2.4.6.3.1. Market
Estimation, 2015 – 2019
10.2.4.6.3.2. Market
Forecast, 2020 – 2028
10.2.4.6.4. South
10.2.4.6.4.1. Market
Estimation, 2015 – 2019
10.2.4.6.4.2. Market
Forecast, 2020 – 2028
10.2.5. Breast
Cancer
10.2.5.1. Definition
10.2.5.2. Market
Penetration, 2018
10.2.5.3. Market
Estimation, 2015 – 2019
10.2.5.4. Market
Forecast, 2020 – 2028
10.2.5.5. Compound
Annual Growth Rate (CAGR)
10.2.5.6. Regional
Bifurcation
10.2.5.6.1. Northeast
10.2.5.6.1.1. Market
Estimation, 2015 – 2019
10.2.5.6.1.2. Market
Forecast, 2020 – 2028
10.2.5.6.2. Midwest
10.2.5.6.2.1. Market
Estimation, 2015 – 2019
10.2.5.6.2.2. Market
Forecast, 2020 – 2028
10.2.5.6.3. West
10.2.5.6.3.1. Market
Estimation, 2015 – 2019
10.2.5.6.3.2. Market
Forecast, 2020 – 2028
10.2.5.6.4. South
10.2.5.6.4.1. Market
Estimation, 2015 – 2019
10.2.5.6.4.2. Market
Forecast, 2020 – 2028
10.2.6. Used in
some Conditioning Regimens Prior to Bone Marrow Transplant
10.2.6.1. Definition
10.2.6.2. Market
Penetration, 2018
10.2.6.3. Market
Estimation, 2015 – 2019
10.2.6.4. Market
Forecast, 2020 – 2028
10.2.6.5. Compound
Annual Growth Rate (CAGR)
10.2.6.6. Regional
Bifurcation
10.2.6.6.1. Northeast
10.2.6.6.1.1. Market
Estimation, 2015 – 2019
10.2.6.6.1.2. Market
Forecast, 2020 – 2028
10.2.6.6.2. Midwest
10.2.6.6.2.1. Market
Estimation, 2015 – 2019
10.2.6.6.2.2. Market
Forecast, 2020 – 2028
10.2.6.6.3. West
10.2.6.6.3.1. Market
Estimation, 2015 – 2019
10.2.6.6.3.2. Market
Forecast, 2020 – 2028
10.2.6.6.4. South
10.2.6.6.4.1. Market
Estimation, 2015 – 2019
10.2.6.6.4.2. Market
Forecast, 2020 – 2028
10.2.7. Non-resectable
Epithelial Carcinoma of the Ovary
10.2.7.1. Definition
10.2.7.2. Market
Penetration, 2018
10.2.7.3. Market
Estimation, 2015 – 2019
10.2.7.4. Market
Forecast, 2020 – 2028
10.2.7.5. Compound
Annual Growth Rate (CAGR)
10.2.7.6. Regional
Bifurcation
10.2.7.6.1. Northeast
10.2.7.6.1.1. Market
Estimation, 2015 – 2019
10.2.7.6.1.2. Market
Forecast, 2020 – 2028
10.2.7.6.2. Midwest
10.2.7.6.2.1. Market
Estimation, 2015 – 2019
10.2.7.6.2.2. Market
Forecast, 2020 – 2028
10.2.7.6.3. West
10.2.7.6.3.1. Market
Estimation, 2015 – 2019
10.2.7.6.3.2. Market
Forecast, 2020 – 2028
10.2.7.6.4. South
10.2.7.6.4.1. Market
Estimation, 2015 – 2019
10.2.7.6.4.2. Market
Forecast, 2020 – 2028
10.2.8. Recurrent
or Unresectable in-transit Metastatic Melanoma
10.2.8.1. Definition
10.2.8.2. Market
Penetration, 2018
10.2.8.3. Market
Estimation, 2015 – 2019
10.2.8.4. Market
Forecast, 2020 – 2028
10.2.8.5. Compound
Annual Growth Rate (CAGR)
10.2.8.6. Regional
Bifurcation
10.2.8.6.1. Northeast
10.2.8.6.1.1. Market
Estimation, 2015 – 2019
10.2.8.6.1.2. Market
Forecast, 2020 – 2028
10.2.8.6.2. Midwest
10.2.8.6.2.1. Market
Estimation, 2015 – 2019
10.2.8.6.2.2. Market
Forecast, 2020 – 2028
10.2.8.6.3. West
10.2.8.6.3.1. Market
Estimation, 2015 – 2019
10.2.8.6.3.2. Market
Forecast, 2020 – 2028
10.2.8.6.4. South
10.2.8.6.4.1. Market
Estimation, 2015 – 2019
10.2.8.6.4.2. Market
Forecast, 2020 – 2028
10.2.9. Treatment
of Amyloidosis with Prednisone
10.2.9.1. Definition
10.2.9.2. Market
Penetration, 2018
10.2.9.3. Market
Estimation, 2015 – 2019
10.2.9.4. Market
Forecast, 2020 – 2028
10.2.9.5. Compound
Annual Growth Rate (CAGR)
10.2.9.6. Regional
Bifurcation
10.2.9.6.1. Northeast
10.2.9.6.1.1. Market
Estimation, 2015 – 2019
10.2.9.6.1.2. Market
Forecast, 2020 – 2028
10.2.9.6.2. Midwest
10.2.9.6.2.1. Market
Estimation, 2015 – 2019
10.2.9.6.2.2. Market
Forecast, 2020 – 2028
10.2.9.6.3. West
10.2.9.6.3.1. Market
Estimation, 2015 – 2019
10.2.9.6.3.2. Market
Forecast, 2020 – 2028
10.2.9.6.4. South
10.2.9.6.4.1. Market
Estimation, 2015 – 2019
10.2.9.6.4.2. Market
Forecast, 2020 – 2028
10.2.10. Adjunct
to Surgery in the Treatment of Breast Cancer
10.2.10.1. Definition
10.2.10.2. Market
Penetration, 2018
10.2.10.3. Market
Estimation, 2015 – 2019
10.2.10.4. Market
Forecast, 2020 – 2028
10.2.10.5. Compound
Annual Growth Rate (CAGR)
10.2.10.6. Regional
Bifurcation
10.2.10.6.1. Northeast
10.2.10.6.1.1. Market
Estimation, 2015 – 2019
10.2.10.6.1.2. Market
Forecast, 2020 – 2028
10.2.10.6.2. Midwest
10.2.10.6.2.1. Market
Estimation, 2015 – 2019
10.2.10.6.2.2. Market
Forecast, 2020 – 2028
10.2.10.6.3. West
10.2.10.6.3.1. Market
Estimation, 2015 – 2019
10.2.10.6.3.2. Market
Forecast, 2020 – 2028
10.2.10.6.4. South
10.2.10.6.4.1. Market
Estimation, 2015 – 2019
10.2.10.6.4.2. Market
Forecast, 2020 – 2028
10.2.11. Others
(Severe Hodgkin Lymphoma, etc.)
10.2.11.1. Definition
10.2.11.2. Market
Penetration, 2018
10.2.11.3. Market
Estimation, 2015 – 2019
10.2.11.4. Market
Forecast, 2020 – 2028
10.2.11.5. Compound
Annual Growth Rate (CAGR)
10.2.11.6. Regional
Bifurcation
10.2.11.6.1. Northeast
10.2.11.6.1.1. Market
Estimation, 2015 – 2019
10.2.11.6.1.2. Market
Forecast, 2020 – 2028
10.2.11.6.2. Midwest
10.2.11.6.2.1. Market
Estimation, 2015 – 2019
10.2.11.6.2.2. Market
Forecast, 2020 – 2028
10.2.11.6.3. West
10.2.11.6.3.1. Market
Estimation, 2015 – 2019
10.2.11.6.3.2. Market
Forecast, 2020 – 2028
10.2.11.6.4. South
10.2.11.6.4.1. Market
Estimation, 2015 – 2019
10.2.11.6.4.2. Market
Forecast, 2020 – 2028
10.3. Key
Segment for Channeling Investments
10.3.1. By
Indication
11. United
States Melphalan Market Analysis and Forecasts, 2020 – 2028
11.1. Overview
11.2. United
States Melphalan Market Revenue (US$ Mn) and Forecasts By Region
11.2.1. Northeast
11.2.1.1. Northeast
Melphalan Market Revenue (US$ Mn) and Forecasts, By Dosage
11.2.1.1.1. Kit
11.2.1.1.2. Tablet,
Film Coated
11.2.1.1.3. Injection
Powder, lyophilized, for Solution
11.2.1.2. Northeast
Melphalan Market Revenue (US$ Mn) and Forecasts, By Route
11.2.1.2.1. Oral
(2 mg/1, 2MG, 5MG)
11.2.1.2.2. Intra-arterial,
Intravenous 50 mg/10 ml
11.2.1.3. Northeast
Melphalan Market Revenue (US$ Mn) and Forecasts, By Indication
11.2.1.3.1. Multiple
Myeloma
11.2.1.3.2. Ovarian
Cancer
11.2.1.3.3. Neuroblastoma
11.2.1.3.4. Rhabdomyosarcoma
11.2.1.3.5. Breast
Cancer
11.2.1.3.6. Used
in some Conditioning Regimens Prior to Bone Marrow Transplant
11.2.1.3.7. Non-resectable
Epithelial Carcinoma of the Ovary
11.2.1.3.8. Recurrent
or Unresectable in-transit Metastatic Melanoma
11.2.1.3.9. Treatment
of Amyloidosis with Prednisone
11.2.1.3.10. Adjunct
to Surgery in the Treatment of Breast Cancer
11.2.1.3.11. Others
(Severe Hodgkin Lymphoma, etc.)
11.2.2. Midwest
11.2.2.1. Midwest
Melphalan Market Revenue (US$ Mn) and Forecasts, By Dosage
11.2.2.1.1. Kit
11.2.2.1.2. Tablet,
Film Coated
11.2.2.1.3. Injection
Powder, lyophilized, for Solution
11.2.2.2. Midwest
Melphalan Market Revenue (US$ Mn) and Forecasts, By Route
11.2.2.2.1. Oral
(2 mg/1, 2MG, 5MG)
11.2.2.2.2. Intra-arterial,
Intravenous 50 mg/10 ml
11.2.2.3. Midwest
Melphalan Market Revenue (US$ Mn) and Forecasts, By Indication
11.2.2.3.1. Multiple
Myeloma
11.2.2.3.2. Ovarian
Cancer
11.2.2.3.3. Neuroblastoma
11.2.2.3.4. Rhabdomyosarcoma
11.2.2.3.5. Breast
Cancer
11.2.2.3.6. Used
in some Conditioning Regimens Prior to Bone Marrow Transplant
11.2.2.3.7. Non-resectable
Epithelial Carcinoma of the Ovary
11.2.2.3.8. Recurrent
or Unresectable in-transit Metastatic Melanoma
11.2.2.3.9. Treatment
of Amyloidosis with Prednisone
11.2.2.3.10. Adjunct
to Surgery in the Treatment of Breast Cancer
11.2.2.3.11. Others
(Severe Hodgkin Lymphoma, etc.)
11.2.3. West
11.2.3.1. West
Melphalan Market Revenue (US$ Mn) and Forecasts, By Dosage
11.2.3.1.1. Kit
11.2.3.1.2. Tablet,
Film Coated
11.2.3.1.3. Injection
Powder, lyophilized, for Solution
11.2.3.2. West
Melphalan Market Revenue (US$ Mn) and Forecasts, By Route
11.2.3.2.1. Oral
(2 mg/1, 2MG, 5MG)
11.2.3.2.2. Intra-arterial,
Intravenous 50 mg/10 ml
11.2.3.3. West
Melphalan Market Revenue (US$ Mn) and Forecasts, By Indication
11.2.3.3.1. Multiple
Myeloma
11.2.3.3.2. Ovarian
Cancer
11.2.3.3.3. Neuroblastoma
11.2.3.3.4. Rhabdomyosarcoma
11.2.3.3.5. Breast
Cancer
11.2.3.3.6. Used
in some Conditioning Regimens Prior to Bone Marrow Transplant
11.2.3.3.7. Non-resectable
Epithelial Carcinoma of the Ovary
11.2.3.3.8. Recurrent
or Unresectable in-transit Metastatic Melanoma
11.2.3.3.9. Treatment
of Amyloidosis with Prednisone
11.2.3.3.10. Adjunct
to Surgery in the Treatment of Breast Cancer
11.2.3.3.11. Others
(Severe Hodgkin Lymphoma, etc.)
11.2.4. South
11.2.4.1. South
Melphalan Market Revenue (US$ Mn) and Forecasts, By Dosage
11.2.4.1.1. Kit
11.2.4.1.2. Tablet,
Film Coated
11.2.4.1.3. Injection
Powder, lyophilized, for Solution
11.2.4.2. South
Melphalan Market Revenue (US$ Mn) and Forecasts, By Route
11.2.4.2.1. Oral
(2 mg/1, 2MG, 5MG)
11.2.4.2.2. Intra-arterial,
Intravenous 50 mg/10 ml
11.2.4.3. South
Melphalan Market Revenue (US$ Mn) and Forecasts, By Indication
11.2.4.3.1. Multiple
Myeloma
11.2.4.3.2. Ovarian
Cancer
11.2.4.3.3. Neuroblastoma
11.2.4.3.4. Rhabdomyosarcoma
11.2.4.3.5. Breast
Cancer
11.2.4.3.6. Used
in some Conditioning Regimens Prior to Bone Marrow Transplant
11.2.4.3.7. Non-resectable
Epithelial Carcinoma of the Ovary
11.2.4.3.8. Recurrent
or Unresectable in-transit Metastatic Melanoma
11.2.4.3.9. Treatment
of Amyloidosis with Prednisone
11.2.4.3.10. Adjunct
to Surgery in the Treatment of Breast Cancer
11.2.4.3.11. Others
(Severe Hodgkin Lymphoma, etc.)
12. Competitive
Benchmarking
12.1. Market
Share Analysis, 2019
12.2. United
States Presence and Growth Strategies
12.2.1. Mergers
and Acquisitions
12.2.2. Product
Launches
12.2.3. Investments
Trends
12.2.4. R&D
Initiatives
13. Player
Profiles
13.1. Acrotech
Biopharma, LLC.
13.1.1. Company
Details
13.1.2. Company
Overview
13.1.3. Product
Offerings
13.1.4. Key
Developments
13.1.5. Financial
Analysis
13.1.6. SWOT
Analysis
13.1.7. Business
Strategies
13.2. ApoPharma
Inc.
13.2.1. Company
Details
13.2.2. Company
Overview
13.2.3. Product
Offerings
13.2.4. Key
Developments
13.2.5. Financial
Analysis
13.2.6. SWOT
Analysis
13.2.7. Business
Strategies
13.3. CELGENE
CORPORATION
13.3.1. Company
Details
13.3.2. Company
Overview
13.3.3. Product
Offerings
13.3.4. Key
Developments
13.3.5. Financial
Analysis
13.3.6. SWOT Analysis
13.3.7. Business
Strategies
13.4. Fresenius
Kabi USA, LLC
13.4.1. Company
Details
13.4.2. Company
Overview
13.4.3. Product
Offerings
13.4.4. Key
Developments
13.4.5. Financial
Analysis
13.4.6. SWOT
Analysis
13.4.7. Business
Strategies
13.5. Ingenus
Pharmaceuticals, LLC
13.5.1. Company
Details
13.5.2. Company
Overview
13.5.3. Product
Offerings
13.5.4. Key
Developments
13.5.5. Financial
Analysis
13.5.6. SWOT
Analysis
13.5.7. Business
Strategies
13.6. Mylan
Inc.
13.6.1. Company
Details
13.6.2. Company
Overview
13.6.3. Product
Offerings
13.6.4. Key
Developments
13.6.5. Financial
Analysis
13.6.6. SWOT
Analysis
13.6.7. Business
Strategies
13.7. Other
Market Participants
14. Key
Findings
Note: This ToC is tentative and can
be changed according to the research study conducted during the course of
report completion.
**Exclusive for Multi-User and
Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.